気管支喘息へのアプローチ　第4版

出版社： 先端医学社
著者：
発行日： 2022-05-10
分野： 臨床医学：内科  >  呼吸器一般
ISBN： 9784865505474
電子書籍版： 2022-05-10 （第4版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

4,950 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,465 円(税込)

購入する

商品紹介

993年に第１版が発行された本シリーズは、新しい喘息診療のエビデンスが示されるごとに版を重ね、喘息診療の現場に活用するポイントをわかりやすく紹介し続けることで、わが国の喘息医療の発展に大きく寄与してきた。第４版となる 本書は、 わが国のガイドラインのみでなく、NAEPP、GINA、英国、オーストラリア、カナダのガイドラインをも参考として、喘息の過去から現在までの医療の変遷や展望喘息治療薬の作用機序や使用法に言及。本書の執筆中に世界に蔓延した COVID-19 と喘息に関しても実地に即して紹介。COPD、喘息とCOPDのオーバーラップ（ACO）についても詳述がなされており、呼吸器領域の医療者必読の一冊。

目次

  • 第1章 気管支喘息について
    第2章 気管支喘息の有病率と自然経過
    第3章 気管支喘息増悪や重症化に影響を与える因子
    第4章 気管支喘息の起こる機序と原因
    第5章 気管支喘息の診断と鑑別すべき疾患
    第6章 気管支喘息の重症度
    第7章 気管支喘息治療薬とその使い方
    第8章 持続性気管支喘息の予防と治療
    　　　　─喘息は管理(コントロール)できる─(わが国と国際的ガイドラインを参考に)
    第9章 気管支喘息急性増悪時の治療と管理─在宅管理を含めて
    第10章 患者－医療者間のパートナーシップと自己管理
    　　　　─良きパートナーシップが喘息管理計画成功の鍵!─
    第11章 特殊な気管支喘息とその治療
    第12章 難治性（重症）気管支喘息
    　　　　―生物学的製剤の使用法も含めて─
    第13章 咳嗽と咳喘息
    第14章 喘息死およびその危険因子と喘息管理における医療者の役割
    第15章 気管支喘息の入院と退院の指標

    附録1 患者さんが知りたい!!気管支喘息 Q&A
    附録2 おもな喘息治療薬

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 気管支喘息について

P.6 掲載の参考文献
1) ポール・マイヤーズ著, 石原俊訳 : レナード・バーンスタイン, アルファベータ, 東京, 2001
 
1) ポール・マイヤーズ著石原俊訳 レナード・バーンスタイン, アルファベータ, 東京, 2001
 
P.8 掲載の参考文献
1) Gross NJ : What is this thing called love? -or, defining asthma. Am Rev Respir Dis 121 : 203-204, 1980
PubMed
2) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2018
 
3) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
4) Mutius E et al : A patient with asthma seeks medical advice in 1828, 1928 and 2012. N Engl J Med 366 : 827-834, 2012
 
5) Dunnill MS : The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol 13 : 27-33, 1960
PubMed
6) Reed CE : New therapeutic approaches in asthma. J Allergy Clin Immunol 77 : 537-543, 1986
PubMed
7) 泉孝英 : 序論 喘息治療の革命-ガイドライン化の意味するもの-. 最新医学 48 : 1975-1983, 1993
Medical*Online
8) Mitsui S : Death from bronchial asthma in Japan. Sino-Jpn J Allergol Immunol 3 : 249-257, 1986
 
9) 佐野靖之ほか : OPINION喘息死ゼロを目指して～内科～. アレルギー・免疫 13 : 1466-1472, 2006
 

第2章 気管支喘息の有病率と自然経過

P.11 掲載の参考文献
i) Hesselmar B et al : Allergy in children in hand versus machine dishwashing. Pediatrics 135 : e590-e597, 2015
PubMed
P.13 掲載の参考文献
1) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
2) 呼吸器疾患. ハリソン内科学 第5版. 福井次矢ほか監訳, メディカル・サイエンス・インターナショナル, 東京, 2017, pp1701-1835
 
3) Weiss ST : Eat dirt--the hygiene hypothesis and allergic diseases. N Engl J Med 347 : 930-931, 2002
PubMed
4) Busse WW et al : Asthma. N Engl J Med 344 : 350-362, 2001
PubMed
5) Wold AE : The hygiene hypothesis revised : is the rising frequency of allergy due to changes in the intestinal flora? Allergy 53 (46 suppl) : 20-25, 1998
 
6) 馬場実 : 小児アレルギー疾患の発症と展開 予防と可能性について. アレルギー 38 : 1061-1069, 1989
 
7) Asthma : the facts, ed by Lane DJ, Oxford University Press, New York, 1996
 

第3章 気管支喘息増悪や重症化に影響を与える因子

P.20 掲載の参考文献
i) Ikeda T et al : Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways. Br J Pharmacol 166 : 1804-1814, 2012
 
P.22 掲載の参考文献
1) ハリソン内科学 第5版, 福井次矢ほか監訳, メディカル・サイエンス・インターナショナル, 東京, 2017
 
2) Jardins TD et al : Clinical Manifestations and Assessment of Respiratory Disease, Mosby/Elsevier, Chicago, 1984, p161
 
3) 職業性アレルギー疾患診療ガイドライン 2016, 日本職業・環境アレルギー学会ガイドライン専門部会監修, 協和企画, 東京, 2016
 
4) National Asthma Education and Prevention Program, Expert Panel Report 2 : Guidelines for the Diagnosis and Management of Asthma, National Institutes of Health, 1997
 
5) Johnston SL et al : Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310 : 1225-1229, 1995
PubMed
6) Bousquet J et al : Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2 LEN and AllerGen). Allergy 63 (s86) : 8-160, 2008
 
7) 浅本仁 : 気管支喘息へのアプローチ 第3版, 先端医学社, 東京, 2006
 
8) Davey G et al : Association between migraine and asthma : matched case-control study. Br J Gen Pract 52 : 723-727, 2002
PubMed
9) Global Initiative for Asthma : Global Strategy for Asthma Management and Prevention, 2020 updated
 
10) 村松芳幸ほか : 喘息と精神・ストレス. アレルギー 67 : 1269-1272, 2018
Medical*Online
11) Haldar P et al : Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178 : 218-224, 2008
PubMed
i) Bousquet J et al : Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2 LEN and AllerGen). Allergy 63 (s86) : 8-160, 2008
 

第4章 気管支喘息の起こる機序と原因

P.26 掲載の参考文献
i) Farah CS et al : The role of small airways in the clinical expression of asthma in adults. J Allergy Clin Immunol 129 : 381-387, 2012
PubMed
P.27 掲載の参考文献
i) Niimi A et al : Effect of short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. Am J Med 116 : 725-731, 2004
PubMed
ii) Grainge CL et al : Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 364 : 2006-2015, 2011
 
iii) Lowry R et al : The effect of anticholinergic bronchodilator therapy on cough during upper respiratory tract infections. Br J Clin Pharmacol 37 : 187-191, 1994
 
P.39 掲載の参考文献
i) 谷口克 : 免疫, その驚異のメカニズム-人体と社会の危機管理, ウェッジ, 東京, 2000
 
P.41 掲載の参考文献
1) Asthma : The fact, ed by Lane DJ, Oxford University Press, New York, 1996
 
2) Smith SG et al : Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol 137 : 75-86, 2016
PubMed
3) 多田富雄 : 免疫・「自己」と「非自己」の科学, 日本放送出版協会, 東京, 2001
 
4) 長瀬洋之 : 専門医のためのアレルギー学講座 免疫・アレルギー疾患の分子標的 喘息における分子標的薬の可能性. アレルギー 64 : 14-22, 2015
 
5) Hasenberg M et al : Cellular immune reactions in the lung. Immunol Rev 251 : 189-214, 2013
PubMed
6) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
7) Wardlaw AJ et al : Eosinophil. In : Bronchial asthma : mechanism and therapeutics, ed by Weiss EB et al, Brown and Company, Boston, 1997, pp258-270
 
8) 坂下雅文ほか : アレルギー性鼻炎の免疫治療とバイオマーカー. アレルギー 67 : 987-994, 2018
Medical*Online
9) Lambrecht BN et al : Allergens and the airway epithelium response : gateway to allergic sensitization. J Allergy Clin Immunol 134 : 499-507, 2014
PubMed
10) 斎藤純平 : 非2型炎症のバイオマーカー. アレルギー 67 : 901-912, 2018
 
11) Holgate ST : Innate and adaptive immune responses in asthma. Nat Med 18 : 673-683, 2012
PubMed
i) 伊藤崇ほか : IL-22と気管支喘息. アレルギー 68 : 923-927, 2019
 
ii) Li Y et al : Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo : a potential biomarker of severe refractory disease. J Immunol 200 : 2253-2262, 2018
 
iii) 中島裕史 : Type2気道炎症における獲得免疫と自然免疫のクロストーク. 日本呼吸器学会誌 8 (suppl) : 115, 2019
 
iv) 長瀬洋之 : 分子標的薬を取り巻く現状と将来展望. 日本呼吸器学会誌 8 (suppl) : 115, 2019
 

第5章 気管支喘息の診断と鑑別すべき疾患

P.47 掲載の参考文献
i) 日本喘息学会. 喘息診療実践ガイドライン 2021, 相良博典, 東田有智監修, 協和企画, 東京, 2021
 
P.49 掲載の参考文献
i) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 
ii) Nadif R et al : Heterogeneity of asthma according to blood inflammatory patterns. Thorax 64 : 374-380, 2009
 
iii) Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report), Global Initiative for Chronlic Obstructive Lung Disease (GOLD), 2020
 
iv) Hartl S et al : Blood eosinophil count in the general population : typical values and potential confounders. Eur Respir J 55 (5) : 1901874, 2020
 
P.50 掲載の参考文献
i) Hastie AT et al : Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 125 : 1028-1036, 2010
PubMed
P.61 掲載の参考文献
i) Juniper EF et al : Development and validation of a questionnaire to measure asthma control. Eur Respir J 14 : 902-907, 1999
PubMed
P.64 掲載の参考文献
i) Turner-Warwick M : On observing patterns of airflow obstruction in chronic asthma. Br J Dis Chest 71 : 73-86, 1977
PubMed
P.66 掲載の参考文献
1) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
2) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
3) The Thoracic Society of Australia and New Zealand. Australian Asthma Handbook, Quick Reference Guide 2019
 
4) Jariwalla G : Epidemiology of asthma and asthma death. In : Asthma, ed by Jariwalla G, MTP Press, Lancaster/Boston, 1988, pp11-58
 
5) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 
6) Jonsson S et al : Comparison of the oral and intravenous routes for treating asthma with methylprednisolone and theophylline. Chest 94 : 723-726, 1988
PubMed
7) 松本久子 : 2型炎症反応を中心とした成人喘息におけるバイオマーカー. アレルギー 67 : 891-900, 2018
Medical*Online
8) Horn BR et al : Total eosinophil counts in the management of bronchial asthma. N Engl J Med 292 : 1152-1155, 1975
PubMed
9) Ortega HG et al : Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds : a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 4 : 549-556, 2016
PubMed
10) Moss RB : Allergy evaluation in children : skin testing and RAST. Am J Asthma Allergy Pediatr 110 : 101-108, 1988
 
11) Sears MR et al : Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 325 : 1067-1071, 1991
PubMed
12) Kharitonov SA et al : Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343 : 133-135, 1994
PubMed
13) Spahn JD et al : Current application of exhaled nitric oxide in clinical practice. J Allergy Clin Immunol 138 : 1296-1298, 2016
PubMed
14) Dweik RA et al : An official ATS clinical practice guideline : interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184 : 602-615, 2011
PubMed
15) Matsunaga K et al : Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. Allergol Int 59 : 363-267, 2010
PubMed
16) Malinovschi A et al : Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity. J Allergy Clin Immunol 138 : 1301-1308, 2016
PubMed
17) Soma T et al : Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma. Allergol Int 67 : S3-S11, 2018
 
18) Izuhara K et al : Roles of periostin in respiratory disorders. Am J Respir Crit Care Med 193 : 949-956, 2016
PubMed
19) Noguchi T et al : Periostin upregulates the effector functions of eosinophils. J Allergy Clin Immunol 138 : 1449-1452, 2016
PubMed
20) Nagasaki T et al : Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma. Allergol Int 66 : 404-410, 2017
PubMed
21) Nagasaki T et al : Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes. J Allergy Clin Immunol 133 : 1474-1477, 2014
PubMed
22) 出原賢治 : アレルギー疾患とペリオスチン. アレルギー 66 : 792-797, 2017
Medical*Online
23) National Asthma Education and Prevention Program, Expert Panel Report 3 : Guidelines for the Diagnosis and Management of Asthma, National Institute of Health, 2007
 
24) Shapiro SM et al : An evaluation of the accuracy of Assess and MiniWright peak flowmeters. Chest 99 : 358-362, 1991
PubMed
25) 日本人のピークフロー値改訂版, 月岡一治監修, 協和企画, 東京, 2002
 
26) British Thoracic Society : The British Guidelines on Asthma Management. 1995 review and position statement. Thorax 52 (S1) : S1-S21, 1997
 
27) Oga T et al : A comparison of the individual best versus the predicted peak expiratory flow in patients with chronic asthma. J Asthma 38 : 33-40, 2001
 
28) Update on Selected Topics in Asthma Management : A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group, National Heart, Lung, and Blood Institute, 2019
 
29) 日本喘息学会 : 喘息診療実践ガイドライン 2021, 相良博典, 東田有智監修, 協和企画, 東京, 2021
 
30) Amerink M et al : Severe adult-onset asthma : a distinct phenotype. J Allergy Clin Immunol 132 : 336-341, 2013
PubMed
31) Haldar P et al : Cluster analysis and clinical asthma phenotypes. A m J Respir Crit Care Med 178 : 218-224, 2008
 
32) 難治性喘息診断と治療の手引き 2019, 日本呼吸器学会編, メディカルレビュー社, 東京, 2018
 
33) Thamrin C et al : Systems biology and clinical practice in respiratory medicine. The Twain shall meet. Am J Respir Crit Care Med 194 : 1053-1061, 2016
PubMed
34) Wenzel SE : Asthma phenotypes : the evolution from clinical to molecular approaches. Nat Med 18 : 716-725, 2012
PubMed
35) Nagasaki T et al : Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes. J Allergy Clin Immunol 133 : 1474-1477, 2014
PubMed
36) 井上純人ほか : 好中球性喘息とは何か. 呼吸器ジャーナル 67 : 224-229, 2019
 
37) Kusano M et al : Development and evaluation of FSSG : frequency scale for the symptoms of GERD. J Gastroenterol 39 : 888-891, 2004
PubMed

第6章 気管支喘息の重症度

P.76 掲載の参考文献
1) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
2) Li JT et al : Attaining optimal asthma control : a practice parameter. J Allergy Clin Immunol 116 : S3-S11, 2005
 
3) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
4) Hodder L et al : Management of acute asthma in adults in the emegency department : nonventilatory management. CMAJ 182 : 265-272, 2010
 
5) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 
6) Australian Asthma Handbook, Quick reference Guide, National Asthma Council Australia, 2016
 
7) McFadden ER Jr et al : Arterial-blood gas tension in asthma. N Engl J Med 278 : 1027-1032, 1968
PubMed
8) Fallot RJ : Acute respiratory failure. In : Current therapy of respiratory disease, ed by Cherniack RM et al, BC Decker, Tronto, 1989, pp337-341
 
9) Scoggin CH : Acute asthma and status asthmatics. In : Clinical strategies in adult asthma, ed by Scoggin CH et al, Lea and Febiger, Philadelphia, 1982, pp34-69
 
10) Jonsson S et al : Comparison of the oral and intravenous routes for treating asthma, with methylprednisolone and theophylline. Chest 94 : 723-726, 1988
PubMed

第7章 気管支喘息治療薬とその使い方

P.82 掲載の参考文献
i) Cramer JA et al : Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J 14 : 25-29, 2007
PubMed
P.87 掲載の参考文献
i) Giraud V et al : Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 19 : 246-251, 2002
 
P.99 掲載の参考文献
i) Johnson M et al : Alternative mechanisms for long-acting β2 adrenergic agonists in COPD. Chest 120 : 258-270, 2001
 
ii) Barnes PJ : Scientific rationale for inhaled combination therapy with long-acting β2 agonists and corticosteroids. Eorr Respir J 19 : 182-191, 2002
 
iii) 新しい診断と治療のABC2-喘息, 泉孝英編, 最新医学社, 大阪, 2011
 
iv) Roux FJ et al : Functional and binding characteristics of long acting β2-agonists in lung and heart. Am J Respir Crit Care Med 153 : 1489-1495, 1996
 
v) Slack RJ et al : In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther 344 : 218-230, 2013
 
vi) 久米裕昭ほか : β2刺激薬の固有活性とそれに基づく臨床投与の実際, アレルギー・免疫 16 : 1604-1614, 2009
 
vii) 久米裕昭ほか. インダカテロール (新規超長時間作用性β2刺激薬) の薬理学的特性とそれに基づく臨床的有用性. アレルギー・免疫 18 : 1958-1968, 2011
 
P.100 掲載の参考文献
i) 久米裕昭ほか : β2刺激薬の固有活性とそれに基づく臨床投与の実際. アレルギー・免疫 16 : 1604-1614, 2009
 
ii) 堀口高彦ほか : 成人気管支喘息患者におけるツロブテロール貼付薬連用による気道炎症及び気道過敏性の推移. 日本呼吸器学会誌 42 : 132-137, 2004
 
iii) 浅本仁 : 喘息予防・管理ガイドライン 2009, 成人喘息の長期管理における薬物療法プランについての私見 : 特にLABAの取扱いについて (Letter to the editor). アレルギー 59 : 1585-1586, 2010
 
P.109 掲載の参考文献
i) Casaburi R et al : Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patient with COPD. Chest 127 : 809-817, 2005
PubMed
ii) 一和多俊男 : プライマリケア医が知っておくべきCOPDの病態と治療. COPDにおける呼吸困難. PROGRESS IN MEDICINE 25 : 955-959, 2005
 
iii) Borg GA : Psychophysical bases of perception. Med Sci Sports Exerc 14 : 377-381, 1982
 
iv) Donohue JF et al : A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122 : 47-55, 2002
PubMed
v) Keating GM : Tiotropium bromide inhalation powder : a review of its use in the management chronic obstructive pulmonary disease. Drugs 72 : 273-300, 2012
 
P.111 掲載の参考文献
i) Peters SP et al : Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 363 : 1715-1726, 2010
PubMed
P.117 掲載の参考文献
i) オーストラリア治療ガイドライン委員会 : 喘息の長期的薬物治療, 呼吸器疾患治療ガイドライン, 浜六郎ほか監訳, NPO法人医薬ビジランスセンター, 大阪, 2001
 
P.128 掲載の参考文献
i) Harrison TW et al : Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations : randomised controlled trial. Lancet 363 : 271-275, 2004
PubMed
ii) Tattersfieid AE et al : Asthma, Lancet 26 : 1313-1322, 2002
 
i) Pauwels RA et al : The inhaled Steroid Treatment As Regular Therapy in early asthma (START) study : rationale and design. Control Clin Trials 22 : 405-419, 2001
PubMed
ii) Todd GR et al : Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 87 : 457-461, 2002
 
P.135 掲載の参考文献
i) Chapman KR et al : Single maintenance and reliever therapy (SMART) of asthma : a critical appraisal. Thorax 65 : 747-752, 2010
PubMed
ii) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Network (SIGN) British Guideline on the Management of Asthma, revised 2019
 
P.136 掲載の参考文献
i) Kemp J et al : Safety of formoterol in adults and children with asthma : a meta-analysis. Ann Allergy Asthma Immunol 197 : 71-78, 2011
 
ii) Thomas M : High-dose inhaled corticosteroids versus add-on long-acting β-agonists in asthma : observational study. J Allergy Clin Immunol 123 : 116-121, 2009
 
iii) Wechsler ME et al : Effect of β2-adrenergic receptor polymorphism on response to long acting β2 agonist in asthma (LARGE trial) : a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 374 : 1754-1764, 2009
 
P.141 掲載の参考文献
i) 矢田純一 : イラスト免疫学, メジカルビュー社, 東京, 1990
 
P.144 掲載の参考文献
1) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
2) Newhause MT et al : Control of asthma by aerosols. N Engl J Med 319 : 870-874, 1986
 
3) Neuman SP et al : Effect of InspirEase on the deposition of metered-dose aerosols in the human respiratory tract. Chest 88 : 551-556, 1986
 
4) 近藤りえ子ほか : 吸入療法ガイド～デバイス選択から吸入指導まで. 日本医事新報 No5022 : 18-36, 2020
 
5) Iwanaga T et al : Aerosol deposition of inhaled corticosteroids/long-acting β2-agonists in the peripheral airways of patients with asthma using functional respiratory imaging, a novel imaging technology. Pulm Ther 3 : 219-231, 2017
 
6) Nelson HS et al : The Salmeterol Muiticenter Asthma Research Trial : a comparson of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 : 15-26, 2006
PubMed
7) Cheung D et al : Long-term effects of a long-acting β2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 327 : 1198-1203, 1992
 
8) 久米裕昭ほか : インダカテロール (新規超長時間作用性β2刺激薬) の薬理学的特性とそれに基づく臨床的有用性. アレルギー・免疫 18 : 1858-1968, 2011
 
9) Salter H : On some points in the treatment and clinical history of asthma. Edinburgh Med J 4 : 1109-1105, 1859
 
10) Herrmann G et al : Successful treatment of persistent extreme dyspnea "status asthmaticus". Use of theophylline ethylene diamine (aminophylline, U. S. P.) intravenously. 1938. J Lab Clin Med 115 : 512-525, 1990
 
11) Barnes PJ : Theophylline. In : Current Review of asthma, ed by Kaliner MA, Current Medicine Group, Philadelphia, 2003, pp173-184
 
12) Bukowskyj M et al : Theophylline reassessed. Ann Intern Med 101 : 63-73, 1984
PubMed
13) Spina D et al : Xanthines an phosphodiesterase inhibitors. In : Pharmacology and therapeutics of asthma and COPD, ed by Page CP et al, Springer Nature, 2017, pp63-91
 
14) Persson CG et al : Pharmacology of anti-asthma xanthines. In : Pharmacology of asthma, ed by Page CP et al Springer-Verlag, New York, 1991, pp207-225
 
15) Ziment I : Respiratory pharmacology and therapeutics, Saunders, Philadelphia, 1978
 
16) Weinberger M et al : Theophylline in asthma. N Engl J Med 334 : 1380-1388, 1996
PubMed
17) Rivington RN et al : Efficacy of uniphyl, salbutamol and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 51 : 325-332, 1995
 
18) 山縣俊之ほか : 吸入抗コリン薬-長時間作動型抗コリン薬チオトロピウムを含む-. 日本胸部臨床 63 : 113-123, 2004
Medical*Online
19) Tattersfield AE et al : Asthma. Lancet 360 : 1313-1322, 2002
PubMed
20) Mackeever T et al : Inhaled corticosteroids and the risk of pneumonia in people with asthma. A case-control study. Chest 144 : 1788-1794, 2013
 
21) Asthma Clinical Research Network (ACRN) Trial-Tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (TALC), ClinicalTrials. gov Identifier : NCT00565266
 
22) Barnes PJ : Distribution of receptor targets in the lung. Proc Am Thorac Soc 1 : 345-351, 2004
 
23) 藤村昭夫 : File No. 35 COPD-抗コリン薬. 日本医事新報 (4945) : 12-13, 2019
Medical*Online
24) Cazzola M et al : Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 64 : 450-504, 2012
PubMed
25) Gosens R et al : Muscalinic receptor signals in pathophysiology of asthma and COPD. Respir Res 7 : 73, 2006
 
26) Grainge CL et al : Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 364 : 2006-2015, 2011
PubMed
27) 玉田勉ほか : 呼吸器疾患の新治療-アノーロ. 呼吸 34 : 491-500, 2015
 
28) 一ノ瀬正和 : チオトロピウム. 分子呼吸器病 8 : 78-80, 2004
 
29) Meurs H et al : Muscarinic receptors on airway mesenchymal cells : novel findings for an ancient target. Pulm Pharmacol Ther 26 : 145-155, 2013
PubMed
30) Costello RW et al : Localizations of eosinophils to airway nerves and effect on neuromel M2 muscarinic receptor function. Am J Physiology 273 : L93-L103, 1997
 
31) Kerstjens HA et al : Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma : two replicate, double-blind, placebo-controlled, parallel- group, active-comparator, randomized trial. Lancet Respir Med 3 : 367-376, 2015
 
32) Matera MG et al : Muscarinic receptor antagonists. In : Pharmacology and therapeutics of asthma and COPD, ed by Page CP et al, Springer Nature, 2017, pp41-62
 
33) Price D et al : Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim Care Respir Med 24 : 14023, 2014
 
34) Suzuki R et al : Changes in muscarinic acetylcholine receptors in guinea-pig lung : effects of aging, inhalation of an allergen, administration of drugs, and vagotomy. Lung 163 : 173-182, 1985
PubMed
35) Schocken DD et al : Reduced β-adrenergic receptor concentrations in aging man. Nature 267 : 856-858, 1977
 
36) Casale TB et al : Tiotropium respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract 6 : 923-936, 2018
PubMed
37) Iwamoto H et al : Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 31 : 1379-1382, 2008
PubMed
38) Osman LM et al : Patient weighing of importance on asthma symptoms. Thorax 56 : 138-142, 2001
 
39) Fukumitsu K et al : Tiotropium attenuates refractory cough and capsaicin cough reflex sensitivity in patients with asthma. J Allergy Clin Immuno Pract 6 : 1613-1620, 2018
 
40) Colak Y et al : Role and impact of chronic cough in individuals with asthma from the general population. J Allergy Clin Immunol Pract 7 : 1783-1792, 2019
PubMed
41) McGarvey L et al : Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials. BMJ Open Respir Res 3 : e000148, 2016
PubMed
42) Kanematsu Y et al : Increased capsaicin sensitivity in patients with severe asthma is associated with worse clinical outcome. Am J Respir Crit Care Med 201 : 1068-1077, 2020
 
43) Ishihara H et al : Muscarinic receptor subtype in feline trachea submucosal gland secretion. Am J physiol 262 : L223-L228, 1992
PubMed
44) Dunnil MS et al : A comparison of the quantitative anatomy of the bronchi in normal subjects. In status asthmatics, in chronic bronchitis and emphysema. Thorax 24 : 176-179, 1969
 
45) Ulrik CS : Outcome of asthma : longitudinal changes in lung function. Eur Respir J 13 : 904-918, 1999
PubMed
46) Teeter JG et al : Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 113 : 272-277, 1998
PubMed
47) Kistemaker LE et al : Acetylcholine beyond bronchoconstriction : roles in inflammation and remodeling. Trends Pharmacol Sci 36 : 164-171, 2015
PubMed
48) Ohta S et al : Effect of tiotropium bromide on airway inflammation and remolding in a mouse of asthma. Clin Exp Allergy 40 : 1266-1275, 2010
 
49) Damara G et al : Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation. Eur J Pharmacol 649 : 349-353, 2010
 
50) Lowry R et al : The effect of anticholinergic bronchodilation therapy on cough during upper respiratory tract infections. Br J Clin Pharmacol 37 : 187-191, 1994
 
51) Ikeda T et al : Regional quantification of muscarinic acetylcholine receptors in human airway. Br J Phrmacol 166 : 1804-1814, 2012
 
52) Cazzola M et al : Triple combinations in chronic obstructive pulmonary disease-is-three better than two? Expert Opin Pharmacother 15 : 2475-2478, 2014
PubMed
53) Garrison SR et al : Nocturnal leg cramps and prescription use that precedes them. A sequence symmetry analysis. Arch Intern Med 172 : 120-126, 2012
PubMed
54) 勝正孝ほか : 副腎皮質ステロイド剤の作用と使い方, 日本アップジョンKK, 東京, 1983
 
55) Baxter JD et al : Hormone receptors. N Engl J Med 301 : 1149-1161, 1979
PubMed
56) Barnes PJ et al : Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157 : S1-S53, 1998
PubMed
57) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
58) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Netwaork (SIGN) : The British Guidelines on Magagement of Asthma, revised 2019
 
59) Oda T et al : A comparison of the individual best versus the predicted peak expiratory flow in patients with chronic asthma. J Asthma 38 : 33-40, 2001
 
60) Dalal AA et al : Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm 22 : 833-843, 2016
PubMed
61) Lefebvre P et al : Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol 136 : 1488-1495, 2015
PubMed
62) Greenberger PA : Corticosteroids in asthma. Rationale, use, and problems. Chest 101 : 418S-421S, 1992
PubMed
63) Barnes PJ : Inhaled glucocorticoids for asthma. N Engl J Med 332 : 868-875, 1995
PubMed
64) Daley-Yates PT : Inhaled corticosteroids : potency, dose equivalence and therapeutic index. Br J Clin Pharmacol 80 : 372-380, 2015
PubMed
65) Salter M et al : Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 293 : L660-L667, 2007
 
66) Biggadike K et al : X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem 51 : 3349-3352, 2008
PubMed
67) 小野寺憲治ほか : 喘息治療薬の開発状況と展望について. 日本薬理学雑誌 116 : 385-394, 2000
Medical*Online
68) 新しい診断と治療のABC2-喘息, 泉孝英編, 最新医学社, 東京, 2011
 
69) Beasley R et al : Inhaled corticosteroid therapy in adult asthma, time for a new therapeutic dose terminology. Am J Respir Crit Care Med 199 : 1471-1477, 2019
PubMed
70) Tattersfield AE et al : Asthma. Lancet 360 : 1313-1322, 2002
PubMed
71) Derendoft H et al : Molecular and clinical pharmacology of internasal corticosteroids : clinical and therapeutic implications. Allergy 63 : 1292-1300, 2008
 
72) Peters SP et al : Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 363 : 1715-1726, 2010
PubMed
73) 新実彰男 : 吸入ステロイド薬の使い分け. アレルギー 65 : 757-763, 2016
Medical*Online
74) 小児気管支喘息治療・管理ガイドライン 2012, 濱崎雄平ほか監修, 日本小児アレルギー学会, 協和企画, 東京, 2011
 
75) 宮川武彦 : 吸入デバイス-患者嗜好を考慮して-. 呼吸療法 2 : 64-73, 2010
 
76) 新実彰男 : Topics 2 治療の進歩 1-吸入ステロイド薬-. 日本呼吸器学会誌 3 : 162-169, 2014
 
77) Derendorf D et al : Molecular and clinical pharmacology of intranasal corticosteroids : clinical and therapeutic implications. Allergy 63 : 1292-1300, 2008
 
78) 玉田勉ほか : 呼吸器疾患の新治療 レルベア・エリプタ. 呼吸 33 : 270-277, 2014
 
79) Kelly HW et al : Effect of inhaled glucocorticoids in childhood on adult height. N Eng J Med 367 : 904-912, 2012
 
80) Rodrigo C et al : Early administration of hydrocortisone in the emergency room treatment of acute asthma : a controlled clinical trial. Respir Med 88 : 755-761, 1994
PubMed
81) Rodrigo GJ et al : Triple inhaled drug protocol for the treatment of acute severe asthma. Chest 123 : 1908-1915, 2003
PubMed
82) Rabe KF et al : Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations : a randomised controlled, double-blind study. Lancet 368 : 744-753, 2006
PubMed
83) Bateman ED et al : Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crin Care Med 170 : 836-844, 2004
 
84) Partridge MR et al : Attitudes and actions of asthma patients on regular maintenance therapy : the INSPIRE study. BMC Pulm Med 6 : 13, 2006
PubMed
85) 久米裕昭 : 気管支拡張薬の使い方. 呼吸 22 : 461-466, 2003
Medical*Online
86) Bateman ED et al : Overall asthma control : the relationship between current control and future risk. J Allergy Clin Immunol 125 : 600-608, 2010
 
87) Ohbayashi H et al : Evaluation of rapid onset of action of ICS/LABA combination therapies on respiratory function in asthma patients : a single-center, open-label, randomized, crossover trial. Pulm Ther 4 : 159-169, 2018
PubMed
88) Becker V et al : Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management. Ther Adv Respir Dis 12 : 1753466618796987, 2018
 
89) 浅本仁ほか : 実臨床におけるフルティフォーム(R) エアゾールの有用性～特にコントロール不良患者に対する早期の臨床効果について～. 吸入療法 7 : 52-59, 2015
 
90) Ishiura Y et al : A comparison of the ethcacy of once-daily fuluticasone furoate/vilanterole with twice-daily fuluticasone propionate/salmeterol in elderly asthmatics. Drug Res 68 : 38-44, 2018
PubMed
91) 大田健 : 成人気管支喘息. アレルギー・免疫 21 : 400-408, 2014
 
92) Bardsley G et al : Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma : a cross-over randomised controlled trial. Respir Res 19 : 133-144, 2018
 
93) Woodcock A et al : Effectiveness on fluticasone furonate plus vilanterol on asthma control in clinical practice : an open-label, parallel group, randomized controlled trial. Lancet 390 : 2247-2255, 2017
 
94) Kornmann O et al : Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma : phase III randomized QUARTZ study findings. Respiratory Med 161 : 105809, 2020
PubMed
95) Wechsler ME et al : Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial) : a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 374 : 1754-1764, 2009
 
96) Rark H-W et al : Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 64 : 778-783, 2009
 
97) Nici L et al : Pharmacologic management of chronic obstructive pulmonary disease, an official American Thoracic Society clinicai practice guideline. Am J Respir Crit Care Med 201 : e56-e69, 2020
 
98) Miravitiles M et al : Estimation of the clinical and economic impact of an improvement in adherence based on the use of once-daily single-controlled triple therapy in patients with COPD. Int J COPD 15 : 1643-1654, 2020
 
99) Luigino Calzetta L et al : Withdrawal of inhaled corticosteroids in COPD : a meta-analysis. Pulm Pharmacol Ther 45 : 148-158, 2017
 
100) Virchow JC et al : Assessing the benefits of triple versus dual fixed-dose combinations for the treatment of severe asthma. Lancet Respr Med 8 : 937-939, 2020
 
101) Holguin F et al : Management of severe asthma : a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 55 : 1900588, 2020
PubMed
102) 浅本仁 : 呼吸器系領域COPDと気管支喘息の新戦略-トリプル製剤の適応-. 日本臨床内科医会会誌 35 : 348, 2021
Medical*Online
103) Feldman G et al : A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5μg compared with tiotropium 18μg in patients with COPD. Int J Chron Obstruct Pulmon Dis 11 : 719-730, 2016
 
104) Lipson DA et al : Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 378 : 1671-1680, 2018
PubMed
105) Lee LA et al : Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN) : a double-blind, randomised, phase 3A trial. Lancet Respir Med 9 : 69-84, 2021
 
106) Ferguson GT et al : Triple combination of budesonide/glycopyrrolate/formoterol fumarate using co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS) a double-blind, parallel-group, randomized controlled trial. Lancet Respir Med 6 : 747-758, 2018
 
107) Rabe KF et al : triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 383 : 35-48, 2020
PubMed
108) Gessner C et al : Fixed-dose combination of indacaterol/glycopyrronium/mometasone furuate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once daily in patients with uncontrolled asthma : a randomized, phase IIIb, non-inferiority study (ARGON). Respir Med 170 : August-September 106021, 2020
 
109) Kerstjens H et al : Once-daily, single-inhaler indacaterol/glycopyrronium/mometasone versus indacaterol/mometasone or twice daily salmeterol/fluchikasone in patients with inadequately controlled asthma (IRIDIUM) : a randomized double-blind, controlled Phase III study. Lancet Resp Med 8 : 1000-1012, 2020
PubMed
110) 2020 Focused Updates to the Asthma Management Guidelines : A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 146 : 1217-1270, 2020
 
111) Lucio J et al : Immunologic mast cell-mediated responses and histamine release are attenuated by heparin. J Appl Physiol 73 : 1093-1101, 1992
PubMed
112) 浅本仁 : 気管支喘息へのアプローチ, 第3版, 先端医学社, 東京, 2006
 
113) 谷崎勝朗 : 気管支喘息におけるヘパリン療法の臨床的検討. 日本胸部疾患学会雑誌 21 : 988-992, 1983
 
114) Moscato G et al : Inhaled furosemide prevents both the bronchoconstriction and the increase in neutrophil chemotactic activity induced by ultrasonic "fog" of distilled water in asthmatics. Am Rev Respi Dis 143 : 561-566, 1991
 
115) Martineau AR et al : Vitamine D for the management of asthma. Cochrane Database Syst Rev 9 : CD011511, 2016
 
116) Till SJ et al : Mechanisms of immunotherapy. J Allergy Clin Immunol 113 : 1025-1034, 2004
PubMed

第8章 持続性気管支喘息の予防と治療 - 喘息の多くは管理 ( コントロール ) できる - ( わが国と国際的ガイドラインを参考に )

P.156 掲載の参考文献
i) Myers TM Guideline for asthma management : a revew and comparison of 5 current guidelines. Respir Care 53 : 751-767, 2008
 
ii) Hodder R et al : Management of acute asthma in adults in the emergency department : non-ventilatory management. CMAJ 182 : E55-E67, 2010
 
iii) Keeley D et al : New guidelines on asthma management. BMJ 314 : 315-316, 1997
 
iv) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 
v) 2020 Focused Updates to the Asthma Management Guideiines : a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 146 : 1217-1270, 2020
 
vi) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
vii) 日本喘息学会 : 喘息診療実践ガイドライン 2021, 相良博典, 東田有智監修, 協和企画, 東京, 2021
 
viii) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2019, 2020, 2021
 
P.159 掲載の参考文献
i) Juniper EF et al : The COAL Committee : identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire Respir Med 100 : 616-621, 2006
 
P.161 掲載の参考文献
i) ダニ対策の実践, 独立行政法人環境再生機構編, 藤澤隆夫監修, 2009
 
P.168 掲載の参考文献
i) Hodder R et al : Management of acute asthma in adults in the emergency department. nonventilatory management. CMAJ 182 : E55-E67, 2010
PubMed
i) 浅本仁 : ステップアップかステップダウンか? -成人気管支喘息の薬剤治療-. アレルギー 61 : 1688-1689, 2012
 
ii) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
iii) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
iv) Wenzel SE : Severe adult asthmas : integrating clinical features, biology, and therapeutics to improve outcomes. Am J Respir Crit Care Med 203 : 809-821 2021
 
P.173 掲載の参考文献
i) Chapman KR et al : Single maintenance and reliever therapy (SMART) of asthma : a critlcal appraisal, Thorax 65 : 747-752, 2010
PubMed
ii) Reddel HK et al : Effect of different asthma treatments on risk of cold-related exacerbations. Eur Respir J 38 : 32-42, 2011
 
iii) 浅本仁ほか : 気管支喘息の急性増悪の予後に対するサルメテロール/フルチカゾンプロピオン酸エステル50μg/500μg配合剤吸入療法の有用性. 日本臨床内科医会会誌 25 : 114-1 20, 2010
 
iv) Bardsley G et al : Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma : a cross-over randomised controlled trial. Respir Res 19133-144, 2018
 
v) Woodcock A et al : Effectiveness on fluticasone furoate plus vilanterol on asthma control in clinical practice : an open-label, parallel group, randomized controlled trial. Lancet 390 : 2247-2255, 2017
 
vi) Beasley R et al : Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am J Respir Crit Care Med 199 : 1471-1477, 2019
 
P.174 掲載の参考文献
i) Kale R : Global campalgn against epilepsy : the treatment gap. Epilepseia 43 (suppl 6) : 31-33, 2002
 
ii) Adachi M et al : Asthma control and quality of life in a real-life setting : a cross-sectional study of adult asthma patients in Japan (ACQUIRE-2). J Asthma 56 : 10] 6-1025, 2019
 
iii) Holguin F et al : Management of severe asthma : a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 55 : 1900588, 2020
 
P.175 掲載の参考文献
1) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
2) Myers TR : Guideline for asthma management : a review and comparison of 5 current guidelines. Respir Care 53 : 751-767, 2008
PubMed
3) National Asthma Council Australia : Asthma Handbook 2020, 2020
 
4) National Asthma Education and Prevention Program, Expert Panel Report 3 : Guidelines for the Diagnosis and Management of Asthma, National Institutes of Health, 2007
 
5) 2020 Focused Updates to the Asthma Management Guidelines : A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 146 : 1217-1270, 2020
 
6) Hodder R et al : Management of acute asthma in adults in the emergency department : nonventilatory management. CMAJ 182 : E55-E67, 2010
PubMed
7) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 
8) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
9) 日本喘息学会 : 喘息診療実践ガイドライン 2021, 相良博典, 東田有智監修, 協和企画, 東京, 2021
 
10) Bateman ED et al : Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 : 836-844, 2004
PubMed
11) Busse WW et al : Asthma. N Engl J Med 344 : 350-362, 2001
PubMed
12) 高野裕久 : 環境ストレスとアレルギー. アレルギー 62 : 548-554, 2013
Medical*Online
13) 福冨友馬ほか : 室内環境中のダニ・昆虫とアレルギー疾患. 室内環境 12 : 87-96, 2009
 
14) 西村秀一 : 高性能の空中浮遊インフルエンザウイルス不活性化を謳う市販各種電気製品の性能評価. 感染症学会雑誌 85 : 537-539, 2011
 
15) Abe K et al : Trends in hospitalizations for asthma during the COVID-190utbreak in Japan. J Allergy Clin Immunol Pract 9 : 494-496, 2021
PubMed
16) Kaye L et al : Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic. J Allergy Clin Immunol Pract 8 : 2384-2385, 2020
PubMed
17) Fanta CH et al : Acute exacerbations of asthma in adults : home and office management. ed by Bochner BS et al, UpToDate 2020 https://www.wolterskluwer.com/en/solutions/uptodate
 
i) Agusti A et al : Treatable traits : toward precision medicine of chronic airway disease. European Respir J 47 : 4101-4149, 2016
 
ii) Shaw DE et al : Balancing the needs of the many and the few : where next for adult asthma guideline. Lancet Respir Med 9 : 786-794, 2021
 
iii) 日本喘息学会 : 喘息診療実践ガイドライン 2021, 相良博典, 東田有智監修, 協和企画, 東京, 2021
 

第9章 気管支喘息急性増悪時の治療と管理 - 在宅管理を含めて

P.187 掲載の参考文献
i) Miyagi S et al : A trial of home oxygen for acute asthma attacks for the prevention of asthmatic death. Intern Med J Thai 1 : 172-175, 2001
 
ii) 宮城征四郎 : 重症喘息発作の治療. アレルギーの臨床 12 : 716-719, 1992
 
i) 浅本仁. 喘息予防・管理ガイドライン 2009, 急性増悪への対応, についての私見-大発作には酸素吸入を最優先に-. アレルギー 59 : 562-563, 2010
 
P.188 掲載の参考文献
1) Hodder R et al : Management of acute asthma in adults in the emergency department ; non-ventilatory treatment. CMAJ 182 : E55-E67, 2010
 
2) National Institute of Health, National Heart, Lung, and Blood Institute : National Asthma Education and Prevention Program, Expert Panel Report 3 : Guidelines for the Diagnosis and Management of Asthma, 2007
 
3) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
4) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 
5) National Asthma Council Australia : Australian Asthma Handbook, Quick reference guide, 2015-2019
 
6) 浅本仁 : 喘息予防・管理ガイドライン 2009, 急性増悪への対応, についての私見-大発作には酸素吸入を最優先に. アレルギー 59 : 562-563, 2010
Medical*Online
7) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
8) Spector SL et al : Practice parameter for the diagnosis and treatment of asthma. J Allergy Clin Immunol 96 : 174-181, 1995
 

第10章 患者 - 医療者間のパートナーシップと自己管理 - 良きパートナーシップが喘息管理計画成功の鍵 ! -

P.200 掲載の参考文献
1) オーストラリア治療ガイドライン委員会 : 喘息の長期的薬物治療, 呼吸器疾患治療ガイドライン, 浜六郎ほか監訳, NPO法人医薬ビジランスセンター, 大阪, 2001
 
2) Asthma Management Handbook 2019, ed by Belby J and Guidelines Committee Australia : National Asthma Council Australia, 2006, 2019
 
3) Asthma : the facts, ed by Lane DJ, Oxford University Press, NewYork, 1996
 
4) International consensus report on diagnosis and treatmant of asthma. National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication no. 92-3091, Eur Respir J 5 : 601-641, 1992
 
5) British Thoracic Society (BTS) /Scottish Intercoliegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 
6) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
ii) Hanania NA et al : The safety and effects of the β-blocker, nadolol, in mild asthma : an open-label pilot study. Pulm Pharmacol Ther 21 : 134-141, 2008
 

第11章 特殊な気管支喘息とその治療

P.205 掲載の参考文献
i) Taniguchi M et al : Aspirin-exacerbated respiratory disease (AERD) : current understanding of AERD. Allergy Int 68 : 289-295, 2019
PubMed
P.209 掲載の参考文献
i) Short PM et al : Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am J Respir Crit Care Med 187 : 1308-1314, 2013
PubMed
P.212 掲載の参考文献
i) Fitch KD : An overview of asthma and airway hyper-responsiveness in Olympic athletes. Br J Sports Med 46 : 413-416, 2012
PubMed
ii) 土肥道子 : 喘息の種々の側面と合併症 2) アスリートの喘息管理. prog Med 35 : 1595-1600, 2015
 
iii) 久田剛志 : アスリート喘息とその対応, アレルギー診療, 永田真編, 医歯薬出版, 東京, 2019, p78
 
iv) 日経メディカルオンライン プライマリケア医のための喘息・COPD入門「うっかりドーピング」にならないために その5, 2021年2月27日
 
v) Stickland MK et al : Effect of warm-up exercise on exercise-induced bronchoconstriction. Med Sci Sports Exerc 44 : 383-391, 2012
 
P.219 掲載の参考文献
i) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
P.220 掲載の参考文献
i) Chan-Yeung M et al : Occupational asthma. N Engl J Med 333 : 107-112, 1995
 
ii) British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 
P.229 掲載の参考文献
1) 谷口正実 : アスピリン喘息 (NSAIDs過敏喘息). 日本内科学会雑誌 102 : 1426-1432, 2013
 
2) 末次勤 : 重症喘息とアスピリン. Excerpta Medica News Letter Allergy Update 1 : 16, 1990
 
3) 浅本仁ほか : 非ステロイド系抗炎症薬による致死的喘息発作症例の臨床的検討. アレルギー 48 : 1230-1237, 1999
Medical*Online
4) オーストラリア治療ガイドライン委員会 : 喘息の長期的薬物治療. 呼吸器疾患治療ガイドライン, 別府宏圀ほか監訳, NPO法人医薬ビジランスセンター, 大阪, 2001, pp97-115
 
5) 医療者のための喘息とCOPDの知識, 泉孝英ほか,編, 医学書院, 東京, 2007
 
6) 職業性アレルギー疾患診療ガイドライン 2016, 職業性アレルギー疾患診療ガイドライン2016作成委員会編, 協和企画, 東京, 2016
 
7) Asthma : the facts, ed by Lane DJ, Oxford University Press, New York, 1996
 
8) 松下祥 : 妊娠と免疫 XV. 妊娠とアレルギー疾患, 専門医のためのアレルギー学講座. アレルギー 63 : 1-5, 2014
 
9) Mayo Clinic Pregnarlcy and asthma ; Managing your symptoms. https://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/pregnancy-and-asthma/art-20047303
 
10) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
11) 釣木澤尚実 : 好酸球性多発血管炎性肉芽腫症の診断と治療. アレルギー 67 : 347, 2018
Medical*Online
12) Khouty P et al : Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 67 : 1149-1156, 2012
PubMed
13) Wechesler WE et al : Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376 : 1921-1932, 2017
PubMed
14) Myers JR et al : Clinical applicability of a methacholine inhalational challenge. JAMA 246 : 225-229, 1981
PubMed
15) Beuther DA et al : Obesity and asthma. Am J Respir Crit Care Med 175 : 112-119, 2006
 
16) 今野哲 : 肥満と気管支喘息. アレルギー 66 : 919-922, 2017
Medical*Online
17) Menezes AMB et al : Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype : COPD-asthma. Chest 145 : 297-304, 2014
PubMed
18) Haldar P et al : Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Mad 178 : 218-224, 2008
 
19) Wang L et al : Sex difference in the association between obesity and asthma in U. S adults : findings from a national study. Respir Med 109 : 955-962, 2005
 
20) Kim HY et al : Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nature Medicine 20 : 54-61, 2014
PubMed
21) Stenius-Aarniala B et al : Immediate and long term effects of weight reduction in obese people with asthma : randomised controlled study, BMJ 320 : 827-831, 2000
PubMed
22) 喘息とCOPDのオーバーラップ診断と治療の手引き 2018, 日本呼吸器学会喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き2018作成委員会編, 日本呼吸器学会, 東京, 2017
 
23) Lipson DA et al : Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 378 : 1671-1680, 2018
PubMed
24) Reiter J et al : Macrolides for the long-term management of asthma--a meta-analysis of exacerbations of randomized clinical trials. Allergy 68 : 1040-1049, 2013
 
25) Suzuki M et al : Asthma-like features and clinical course of COPD : an analysis from the Hokkaido COPD cohort study. Am J Respir Crit Care Med 194 : 1358-1365, 2016
PubMed
26) 權寧博 : 第28回国際喘息学会日本・北アジア部会プログラム抄録集, 2019, p45
 
27) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
28) Dunn RM et al : Asthma in the elderly and late-onset adult asthma. Allergy 73 : 284-294, 2018
PubMed
29) Chen FJ et al : Importance of fraction exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome, asthma and COPD. Int J Chron Obstruct Pulmon Dis 11 : 2385-2390, 2016
 
30) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 

第12章 難治性 ( 重症 ) 気管支喘息 - 生物学的製剤の使用法も含めて -

P.234 掲載の参考文献
i) Chung KF et al : International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 : 343-373, 2014
PubMed
ii) 重症喘息-定義, 評価, 治療に関するERS/ATSガイドライン (日本語訳), 一ノ瀬正和監修, メディカルレビュー社, 東京, 2014
 
i) Corrigan CJ et al : Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticold receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 144 : 1016-1025, 1991
 
ii) Kerstjens HA et al : Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 367 : 1198-1207, 2012
 
P.236 掲載の参考文献
i) Hekking PP et al : The prevalence of severe refractory asthma. J Allergy Clin Immunol 135: 896-902, 2015
 
P.238 掲載の参考文献
i) Miller BD : Depression and asthma : a poteitially lethal mixture. J Allergy Clin Immunol 80 : 481-486, 1987
PubMed
P.246 掲載の参考文献
i) Holguin F et al : Management of severe asthma : a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 55 : 1900588, 2020
PubMed
P.251 掲載の参考文献
1) Chung KF et al : International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 : 343-373, 2014
PubMed
2) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
3) Ebmeier S et al : Trends in international asthma mortality : analysis of data from the WHO mortality database from 46 countries (1993-2012). Lancet 390 : 935-945, 2017
PubMed
4) 難治性喘息診断と治療の手引き 2019, 日本呼吸器学会難治性喘息診断と治療の手引き2019作成委員会編, メディカルレビュー社, 東京, 2018
 
5) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
6) Smith SG et al : Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol 137 : 75-86 e8, 2016
 
7) Wenzel SE et al : Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160 : 1001-1008, 1999
PubMed
8) Haldar P et al : Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178 : 218-224, 2008
PubMed
9) 浅野浩一郎 : 重症喘息の病型と病態. 日本臨床内科医会会誌 33 : 331-333, 2018
Medical*Online
10) 松本久子 : 現適応薬総論～分子標的薬の使い分けをどのように考えるか～. 医薬ジャーナル 54 : 2423-2428, 2018
 
11) Beasley R et al : Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am J Respir Crit Care Med 199 : 1471-1477, 2019
PubMed
12) Tattersfield AE et al : Asthma. Lancet 360 : 1313-1322, 2002
PubMed
13) Gosens R et al : Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 7 : 73, 2006
PubMed
14) Zervas E et al : An algorithmic approach for the treatment of severe uncontrolled asthma. URJ Open Res 4, 2018
 
15) Haughney J et al : A retrospective cohort study in severe asthma describing commonly measured biomarkers : eosinophil count and IgE levels. Respir Med 134 : 117-123, 2018
PubMed
16) 多賀谷悦子 : 特殊な治療 生物学的製剤と気管支熱形成術. 日本内科学会雑誌 108 : 1156-6112, 2019
 
17) IgE抗体陽性難治性喘息に対する治療戦略を探る. ～抗体治療時代の～気管支喘息治療の新たなストラテジー, 太田健編, 先端医学社, 東京, 2011, pp136-141
 
18) 川島彬子ほか : 抗IgE抗体治療・アレルゲン免疫療法の現在とその展望. 日本医事新報 No4510 : 51-55, 2010
 
19) Hanania NA et al : Exploring the effects of omalizumab in allergic asthma : an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187 : 804-811, 2013
PubMed
20) Holgate S et al : The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115 : 459-456, 2005
PubMed
21) Novelli F et al : Asthma control in severe asthmatics under treatment with omalizumab : a cross-sectional observational study in Italy. Pulm Pharmacol Thera 31 : 123-129, 2015
 
22) Busse WW et al : Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364 : 1005-1015, 2011
PubMed
23) Nopp A et al : After 6 years with Xolair ; a 3-year withdrawal follow-up. Allergy 65 : 56-60, 2010
PubMed
24) Nissim Ben Efraim AH et al : Tissue remodeling and angiogenesis in asthma : the role of the eosinophil. Adv Resp Dis 2 : 163-171, 2008
 
25) Ortega HG et al : Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds : a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 4 : 549-556, 2016
PubMed
26) Ortega HG et al : Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 : 1198-1207, 2014
PubMed
27) Israel F et al : Severe and difficult-to-treat asthma in adults. N Ingl J Med 377 : 965-976, 2017
 
28) 長瀬洋之 : 非2型炎症標的薬とToll-like受容体リガンドによる喘息治療戦略. アレルギー 68 : 125-131, 2019
Medical*Online
29) Wenzel S et al : Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist : a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 368 : 34-44, 2016
 
30) Castro M et al : Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378 : 2486-2496, 2018
PubMed
31) Wechsler ME et al : Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE) : an open-label extension study. Lancet Respir Med 10 : 11-25, 2022
PubMed
32) Bachert C et al : Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyp (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) results from two multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 3 trials. Lancet 394 : 1638-1650, 2019
PubMed
33) Menzies-Gow A et al : Tezepelumab in adults adolescents with severe, uncontrolled asthma. N Engl J Med 384 : 1800-1809, 2021
PubMed
34) Svenningsen S et al : Clinical biomarkers and noninvasive assessment of severe asthma. Eur Respir Mon 84 : 93-112, 2019
 
35) Castro M et al : Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma : a multicenter, randomized, double-blind, sham-controlled clinical trial. Amer J Respir Crit Care Med 181 : 116-124, 2010
 
36) Laxmanan B et al : Bronchial thermoplasty in asthma : current perspectives. J Asthma. Allergy 8 : 39-49, 2015
PubMed

第13章 咳嗽と咳喘息

P.263 掲載の参考文献
i) Morice AH et al : A worldwide survey of chronic cough : a manifestation of enhanced somatosensory response Eur Respir J 44 : 1149-1155, 2014
PubMed
P.265 掲載の参考文献
1) 咳嗽・喀痰の診療ガイドライン 2019, 日本呼吸器学会咳嗽・喀痰の診療ガイドライン2019作成委員会編, メディカルレビュー社, 東京, 2019
 
2) 藤森勝也ほか : 長引く咳嗽, 鑑別診断, 問診. 日本医事新報 No4593 : 40-44, 2012
 
3) 田尻智子ほか : 当院呼吸器科外来における急性咳嗽の原因疾患に関する検討. アレルギー 67 (1) : 46-52, 2018
Medical*Online
4) 新実彰男 : 慢性咳嗽の診断と治療Overview. アレルギー 56 (2) : 85-88, 2007
Medical*Online
5) Morimoto C et al : Gastroesophageal reflux disease is a risk factor for sputum production in the general population : the Nagahama study. Respir Res 22 : 6, 2021
PubMed
6) Niimi A et al : Eosinophilic inflammation in cough variant asthma. Eur Respir J 11 : 1064-1069, 1998
PubMed
7) Glauser FL : Variant asthma. Ann Allergy 30 : 457-459, 1972
PubMed
8) 藤村政樹 : 咳喘息とアトピー咳嗽. 日本内科学会雑誌 93 : 1200-1205, 2004
 
9) 咳嗽に関するガイドライン 第2版, 日本呼吸器学会咳嗽に関するガイドライン第2版作成委員会編, 日本呼吸器学会, 東京, 2012
 
10) Tajiri T et al : Prevalence and clinical relevance of allergic rhinitis in patients with classic asthma and cough variant asthma. Respiration 87 : 211-218, 2014
PubMed
11) 中山昌彦 : 咳喘息の呼吸機能について-PEF/FEV1低下が特徴. 京都医学会雑誌 67 : 75-80, 2020
Medical*Online
12) 新実彰男 : 第5回総合アレルギー講習会記録, 2019, p84
 
13) 藤村政樹 : 慢性咳嗽を診る, 医薬ジャーナル社, 大阪, 2002
 
14) Gibson PG et al : Chronic cough : eosinophilic bronchitis without asthma. Lancet 1 : 1346-1348, 1989
 
15) Irwin RS et al : Postnasal drip and cough. Clin Notes. Respir Dis 18 : 11-12, 1980
PubMed
16) Warg TY et al : Chronic cough and obstructive sleep apnoea in a sleep laboratory-based pulmonary practice. Cough 9 : 24, 2014
 
17) Ryan NM et al : Gabapentin for refractory chronic cough : a randomized, double-blined, placebo-controlled trial. Lancet 380 : 1583-1589, 2012
 
18) 新実彰男 : 咳喘息とアトピー咳嗽, 永田真編, 医学のあゆみBOOKSトータルアプローチ アレルギー診療重要基礎知識 40, 医歯薬出版, 東京, 2019, pp100-104
 
19) 新実彰男 : 咳嗽診療の心得-たかが咳, されど咳-. 日本内科学会雑誌 109 : 2091-2094, 2020
 
20) Smith JA et al : Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough : a randomized, double-blind, parallel-group phase 2b trial. Lancet Respir Med 8 : 775-785, 2020
 
21) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 

第14章 喘息死およびその危険因子と喘息管理における医療者の役割

P.273 掲載の参考文献
1) 足立満ほか : 本邦における高齢者喘息の現状と課題. アレルギー・免疫 16 : 248-259, 2010
 
2) 浅本仁ほか : 非ステロイド系抗炎症薬による致死的喘息発作症例の臨床的検討. アレルギー 48 : 1230-1237, 1999
Medical*Online
3) 喘息予防・管理ガイドライン 2021 (JGL2021), 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 東京, 2021
 
4) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 

第15章 気管支喘息の入院と退院の指標

P.277 掲載の参考文献
1) Turner-Warwick M : On observing patterns of airflow obstruction in chronic asthma. Br J Dis Chest 71 : 73-86, 1977
PubMed

[附録 1] 患者さんが知りたい ! ! 気管支喘息Q & A

P.288 掲載の参考文献
1) Grainge CL et al : Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 364 : 2006-2015, 2011
PubMed
2) Suissa S et al : Use of anti-inflammatory therapy and asthma mortality in Japan. Eur Respir J 21 : 101-104, 2003
PubMed
3) Haalboom JR et al : Effect of fenoterol on plasma potassium and cardiac ectopic activity. Lancet ii : 45, 1989
 
4) Garrett JE et al : Risk of severe life threatening asthma and β agonist type : an example of confounding by severity. Thorax 51 : 1093-1099, 1996
 
5) Global Initiative for Asthma (GINA) : Global Strategy for Asthma Management and Prevention, updated 2021
 
6) British Thoracic Society (BTS) /Scottish Intercollegiate Guidelines Network (SIGN) : British Guideline on the Management of Asthma, revised 2019
 

書評

最近チェックした商品履歴

Loading...